Findings showed a statistically significant reduction in proptosis in the linsitinib 150mg twice daily group, with a proptosis responder rate of 52% at week 24. Topline results were announced from ...

The trial achieved its primary endpoint of proptosis reduction with linsitinib 150 mg. There were no drug-related hearing impairments, significant hyperglycemia or menstrual changes. Linsitinib ...